Journey Medical Corporation (DERM)
After hours:
| Previous close | 3.5100 |
| Open | 3.6100 |
| Bid | 3.5100 x 100 |
| Ask | 3.7000 x 100 |
| Day's range | 3.4101 - 3.6300 |
| 52-week range | 1.0200 - 8.1100 |
| Volume | |
| Avg. volume | 157,585 |
| Market cap | 72.354M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 20 May 2024 - 24 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.83 |
GlobeNewswireJourney Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as t
- GlobeNewswire
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Pla
GuruFocus.comDirector Justin Smith Acquires 30,000 Shares of Journey Medical Corp (DERM)
Journey Medical Corp (NASDAQ:DERM) has reported an insider purchase according to the latest SEC filings.
